The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors
Open accessAbstract
Mutationally activated BRAF V600E (BRAF VE) is detected in ∼6% of human malignancies and promotes sustained MEK1/2–ERK1/2 pathway activation. We have designed BRaf CA mice to express normal BRaf prior to Cre-mediated recombination after which BRaf VE is expressed at physiological levels. BRaf CA mice infected with an Adenovirus expressing Cre recombinase developed benign lung tumors that only rarely progressed to adenocarcinoma. Moreover, BRaf VE-induced lung tumors were prevented by pharmacological inhibition of MEK1/2. BRaf VE expression initially induced proliferation that was followed by growth arrest bearing certain hallmarks of senescence. Consistent with Ink4a/Arf and TP53 tumor suppressor function, BRaf VE expression combined with mutation of either locus led to cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,195
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 3×
“Oncogene-induced cell cycle arrest with features of senescence (OIS) is reported to be a cellular defense mechanism restraining the proliferation of normal cells in response to inappropriate activation of RAS or its signaling effectors (Collado et al. 2005; Michaloglou et al. 2005).”
BackgroundResultAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Self-citationTargeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Cited by
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
“Oncogenic Ras and Raf, however, induce p21-dependent senescenc”
BackgroundHerbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086
“…in various in vivo lesions, including human melanocytic nevi (Michaloglou et al., 2005; Gray-Schopfer et al., 2006), murine lung adenomas (Dankort et al., 2007), human dermal neurofibromas (Courtois-Cox et al., 2006), human and murine prostatic adenomas (Chen et al., 2005), murine…”
BackgroundCellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
“In addition, mice that express endogenous levels of Braf V600E develop benign lung tumours that rarely progress to adenocarcinoma and show features of senescenc”
BackgroundUnravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
Living on a break: cellular senescence as a DNA-damage response
d'Adda di Fagagna, F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2440 · Cited by 1,170
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citationSenescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Self-citationThe Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 894
Antioxidants Accelerate Lung Cancer Progression in Mice
Sayin, V. I., Ibrahim, M. X., Larsson, E., Nilsson, J. A., Lindahl, P., & Bergo, M. O. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007653 · Cited by 867
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Self-citationVemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 691
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Kaplon, J., Zheng, L., Meissl, K., Chaneton, B., Selivanov, V. A., Mackay, G., van der Burg, S. H., Verdegaal, E. M. E., Cascante, M., Shlomi, T., et al. (2013) · Nature · doi:10.1038/nature12154 · Cited by 633
Copper is required for oncogenic BRAF signalling and tumorigenesis
Brady, D. C., Crowe, M. S., Turski, M. L., Hobbs, G. A., Yao, X., Chaikuad, A., Knapp, S., Xiao, K., Campbell, S. L., Thiele, D. J., et al. (2014) · Nature · doi:10.1038/nature13180 · Cited by 609
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Berres, M.-L., Lim, K. P. H., Peters, T., Price, J., Takizawa, H., Salmon, H., Idoyaga, J., Ruzo, A., Lupo, P. J., Hicks, M. J., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130977 · Cited by 442
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of Braf V600E–Driven Lung Tumors
Strohecker, A. M., Guo, J. Y., Karsli-Uzunbas, G., Price, S. M., Chen, G. J., Mathew, R., McMahon, M., & White, E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0397 · Cited by 435
Self-citationPIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
Many roads lead to oncogene-induced senescence
Courtois-Cox, S., Jones, S. L., & Cichowski, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210950 · Cited by 397
“However, several reports have now demonstrated that oncogene-induced senescence does indeed occur in vivo in human tumors and in mouse tumor models (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005; Courtois-Cox et al., 2006; Dankort et al., 2007; Sarkisian et al., 2007).”
BackgroundAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
Succony, L., Rassl, D., Barker, A., McCaughan, F., & Rintoul, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102237 · Cited by 342
Healing and Hurting: Molecular Mechanisms, Functions, and Pathologies of Cellular Senescence
Adams, P. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.021 · Cited by 326
Tumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B., Dankort, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320
Self-citationWhite, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026120 · Cited by 320
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley, M. J., Cardona, D. M., Lazarides, A. L., Spasojevic, I., Ferrer, J. M., Cahill, J., Lee, C.-L., Snuderl, M., Blazer, D. G., Hwang, E. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0293 · Cited by 296
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Aird, K. M., Zhang, G., Li, H., Tu, Z., Bitler, B. G., Garipov, A., Wu, H., Wei, Z., Wagner, S. N., Herlyn, M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.004 · Cited by 285
“In addition, there is evidence to suggest that the progression of benign nevi with oncogenic BRAF or NRAS into malignant melanoma correlates with OIS bypass (Dankort et al., 2007; Dhomen et al., 2009; Kuilman et al., 2010).”
BackgroundBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
Self-citationElucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Self-citationOncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Characterization of novel markers of senescence and their prognostic potential in cancer
Althubiti, M., Lezina, L., Carrera, S., Jukes-Jones, R., Giblett, S. M., Antonov, A., Barlev, N., Saldanha, G. S., Pritchard, C. A., Cain, K., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.489 · Cited by 256
Senescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Atg7 Overcomes Senescence and Promotes Growth of Braf V600E-Driven Melanoma
Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1473 · Cited by 208
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
Souroullas, G. P., Jeck, W. R., Parker, J. S., Simon, J. M., Liu, J.-Y., Paulk, J., Xiong, J., Clark, K. S., Fedoriw, Y., Qi, J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4092 · Cited by 212
“This suggests that Ezh2 Y641F activates certain silenced genes and silences certain activated genes.”
K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Deconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194
Stable Cellular Senescence Is Associated with Persistent DDR Activation
Fumagalli, M., Rossiello, F., Mondello, C., & d’Adda di Fagagna, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110969 · Cited by 183
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“The growth of these cancers was dependent on persistent oncogene expression, suggesting that mutant BRAF may also be necessary for tumour maintenance.(96,97) Paik and colleagues showed that patients with lung adenocarcinomas who were current or former smokers had a”
BackgroundMLL1 is essential for the senescence-associated secretory phenotype
Capell, B. C., Drake, A. M., Zhu, J., Shah, P. P., Dou, Z., Dorsey, J., Simola, D. F., Donahue, G., Sammons, M., Rai, T. S., et al. (2016) · Genes & Development · doi:10.1101/gad.271882.115 · Cited by 156
Carragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
“As in mice manipulated to express V600EBraf in the lung (Dankort et al, 2007) and melanocytes (Dhomen et al, 2009), we show here that V600EBraf induces oncogene-induced senescence (OIS) in the intestine following an initial wave of hyperplasia.”
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137
Köhler, C., Nittner, D., Rambow, F., Radaelli, E., Stanchi, F., Vandamme, N., Baggiolini, A., Sommer, L., Berx, G., van den Oord, J. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.003 · Cited by 126
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Regulation of senescence and the SASP by the transcription factor C/EBPβ
Salotti, J., & Johnson, P. F. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110752 · Cited by 103
Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
Cisowski, J., Sayin, V. I., Liu, M., Karlsson, C., & Bergo, M. O. (2016) · Oncogene · doi:10.1038/onc.2015.186 · Cited by 104
Kriegl, L., Neumann, J., Vieth, M., Greten, F. R., Reu, S., Jung, A., & Kirchner, T. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.43 · Cited by 99
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
Reuter, J. A., Ortiz-Urda, S., Kretz, M., Garcia, J., Scholl, F. A., Pasmooij, A. M. G., Cassarino, D., Chang, H. Y., & Khavari, P. A. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.002 · Cited by 88
Zhang, P., Guan, H., Yuan, S., Cheng, H., Zheng, J., Zhang, Z., Liu, Y., Yu, Y., Meng, Z., Zheng, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29000-5 · Cited by 86
Suppression of p16 alleviates the senescence-associated secretory phenotype
(2021) · doi:10.18632/aging.202640 · Cited by 84
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology
Bigenwald, C., Le Berichel, J., Wilk, C. M., Chakraborty, R., Chen, S. T., Tabachnikova, A., Mancusi, R., Abhyankar, H., Casanova-Acebes, M., Laface, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01304-x · Cited by 83
Maddodi, N., Huang, W., Havighurst, T., Kim, K., Jack Longley, B., & Setaluri, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.26 · Cited by 80
“, an initial proliferative burst followed by senescence (Michaloglou et al., 2005; Dankort et al., 2007).”
InfluentialEvidence of oncogene-induced senescence in thyroid carcinogenesis
Vizioli, M. G., Possik, P. A., Tarantino, E., Meissl, K., Borrello, M. G., Miranda, C., Anania, M. C., Pagliardini, S., Seregni, E., Pierotti, M. A., et al. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0240 · Cited by 47
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
Self-citationReischmann, N., Andrieux, G., Griffin, R., Reinheckel, T., Boerries, M., & Brummer, T. (2020) · Oncogene · doi:10.1038/s41388-020-01414-9 · Cited by 37
Zhang, Z., Wu, Y., Fu, J., Yu, X., Su, Y., Jia, S., Cheng, H., Shen, Y., He, X., Ren, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48173-9 · Cited by 14
“TPO-Cre mice were kindly gifted from Dr Shioko Kimura 64 , LSL-Braf V600E CA mice were kindly gifted from Dr Martin McMahon 65 .”
Method
Metadata
- Authors
- Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-02-13
- Volume
- 21
- Issue
- 4
- Pages
- 379-384
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2142020978
- Cited by
- 481
- References
- 25
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.